These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 19531897)
1. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897 [TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210 [TBL] [Abstract][Full Text] [Related]
3. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986 [TBL] [Abstract][Full Text] [Related]
4. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. Tazaki J; Jinnai T; Tada T; Kato Y; Makiyama T; Ikeda T; Yamane K; Naruse Y; Takahashi K; Watanabe H; Kimura T; Horiuchi H J Atheroscler Thromb; 2012; 19(2):186-93. PubMed ID: 22166969 [TBL] [Abstract][Full Text] [Related]
5. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Namazi S; Kojuri J; Khalili A; Azarpira N Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274 [TBL] [Abstract][Full Text] [Related]
7. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375 [TBL] [Abstract][Full Text] [Related]
8. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178 [TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794 [TBL] [Abstract][Full Text] [Related]
11. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. Nakata T; Miyahara M; Nakatani K; Wada H; Tanigawa T; Komada F; Hoshino K; Aoki T; Nishimura Y; Tamaru S; Ito M; Nishikawa M; Circ J; 2013; 77(6):1436-44. PubMed ID: 23470885 [TBL] [Abstract][Full Text] [Related]
12. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
13. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response. Shalia KK; Shah VK; Pawar P; Divekar SS; Payannavar S Indian Heart J; 2013; 65(2):158-67. PubMed ID: 23647895 [TBL] [Abstract][Full Text] [Related]
15. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. Gurbel PA; Bliden KP; Antonino MJ; Stephens G; Gretler DD; Jurek MM; Pakyz RE; Shuldiner AR; Conley PB; Tantry US J Thromb Haemost; 2010 Jan; 8(1):43-53. PubMed ID: 19817997 [TBL] [Abstract][Full Text] [Related]
16. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648 [TBL] [Abstract][Full Text] [Related]
17. Genetic determinants of response to clopidogrel and cardiovascular events. Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L; N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083 [TBL] [Abstract][Full Text] [Related]
18. [Genetic variability in the efficacy of clopidogrel]. Kristensen KE; Rasmussen HB; Hansen PR Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885 [TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Mejin M; Tiong WN; Lai LY; Tiong LL; Bujang AM; Hwang SS; Ong TK; Fong AY Int J Clin Pharm; 2013 Aug; 35(4):621-8. PubMed ID: 23661171 [TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]